Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Phase 1 Completed
100 enrolled
Phase Ib of L-NMMA and Pembrolizumab
Phase 1 Completed
12 enrolled 15 charts
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Phase 1 Completed
25 enrolled 12 charts
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Phase 1 Completed
16 enrolled 13 charts
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
MK-4700-001
Phase 1 Completed
5 enrolled
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1 Completed
62 enrolled 17 charts
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
Phase 1 Completed
83 enrolled 13 charts
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Phase 1 Completed
25 enrolled 14 charts
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
Phase 1 Completed
2 enrolled
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Phase 1 Completed
32 enrolled 23 charts
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
80 enrolled
PEMBIB
Phase 1 Completed
196 enrolled
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Phase 1 Completed
23 enrolled 11 charts
FORTIFY
Phase 1 Completed
14 enrolled
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Phase 1 Completed
27 enrolled
EIK1001
Phase 1 Completed
87 enrolled
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Completed
1 enrolled
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1 Completed
145 enrolled
MK-5890-001
Phase 1 Completed
182 enrolled 36 charts
MK-1454-001
Phase 1 Completed
156 enrolled 20 charts
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
Phase 1 Completed
13 enrolled
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
KEYVIBE-001
Phase 1 Completed
474 enrolled 39 charts
MK-4464-001
Phase 1 Completed
64 enrolled
Pembrolizumab in Combination With CRT for LA-SCCHN
Phase 1 Completed
59 enrolled 9 charts
MK-4830-001
Phase 1 Completed
470 enrolled
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Phase 1 Completed
21 enrolled 12 charts
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Phase 1 Completed
16 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
Phase 1 Completed
28 enrolled
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Phase 1 Completed
34 enrolled 28 charts
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Phase 1 Completed
146 enrolled 38 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
P102
Phase 1 Completed
151 enrolled
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Phase 1 Completed
109 enrolled
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Phase 1 Completed
174 enrolled
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1 Completed
185 enrolled 28 charts
MK-3475-A17
Phase 1 Completed
19 enrolled 14 charts
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Phase 1 Completed
18 enrolled
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Phase 1 Completed
199 enrolled
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1 Completed
56 enrolled 19 charts
MK-0482-001
Phase 1 Completed
222 enrolled
MK-6598-001
Phase 1 Completed
90 enrolled
MK-4280-001
Phase 1 Completed
481 enrolled 36 charts
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
Phase 1 Completed
15 enrolled 19 charts
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Phase 1 Completed
41 enrolled
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Completed
169 enrolled
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Phase 1 Completed
72 enrolled